Clinical Research Directory

Inclusion Criteria: * Diagnosis of metastatic colorectal adenocarcinoma with liver dominant disease * Diagnosis of liver metastasis may be made by histo- or cyto-pathology, or by clinical and imaging criteria. * The Liver metastasis are not eligible for resection, RFA or SBRT * All patients must be off all chemotherapeutic regimens for 14 days prior to SIRT treatment * All patients must be off vascular endothelial growth factor inhibitors for 6 weeks prior to SIRT treatment * Progressive disease, severe intolerance during or following all standard lines of chemo-therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Age 18 years or older * Able to understand written information * Consent to samples for translational research Exclusion Criteria: * Pretherapeutic work-up procedure with Tc-99m macroaggregated albumin (MAA) scintigraphy showing extrahepatic foci in GI-tract * Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition * Previous radiation therapy to the lungs and/or to the upper abdomen overlapping with dose to the liver at interventionist´s decision * Lung shunt greater than 20% or \> 30 Gray radiation absorbed dose to the lungs, at estimated by Tc-99m-MAA * Pregnancy * Symptomatic lung disease precluding SIRT at interventionist´s decision * Active uncontrolled infection * Any pre-treatment laboratory findings within 30 days of treatment demonstrating: alanine aminotransferase level greater than 5 times upper normal limit and/or serum bilirubin greater than 2 mg/dl (\>34 umol/l) * Current or previously evidence of ascites on CT-scan or physical examination * Tumour volume greater than 50% of liver volume * Conditions precluding translational samples